437 related articles for article (PubMed ID: 36620297)
1. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.
Yang L; Xu L; Guo Q; Deng B; Hong Y; Wang L; Wang Y; Jiang D; Ren H
Int J Med Sci; 2023; 20(6):737-748. PubMed ID: 37213672
[No Abstract] [Full Text] [Related]
4. Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer.
Song R; Liu L; Pan Q; Liu J; Tan J; Deng J; Deng Q; Lin Z; Chen M; Peng M; Ren H; Ming J
Front Immunol; 2022; 13():1028246. PubMed ID: 36353624
[TBL] [Abstract][Full Text] [Related]
5. Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study.
Zhang S; He J; Tang B; Zhou Q; Hu Y; Yu Y; Chen J; Liu Y; Li C; Ren H; Liao X
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769873
[TBL] [Abstract][Full Text] [Related]
6. The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients.
Yang L; Xiang F; Wang D; Guo Q; Deng B; Jiang D; Ren H
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):503-512. PubMed ID: 36849838
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.
Li T; Song R; Wang J; Zhang J; Cai H; He H; Hu W; Yu D; Wang C; Pan Q; Peng M; Ren H; Zhu P
Int J Infect Dis; 2022 Sep; 122():874-884. PubMed ID: 35905950
[TBL] [Abstract][Full Text] [Related]
8. Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines.
Xiang F; Long B; He J; Cheng F; Zhang S; Liu Q; Chen Z; Li H; Chen M; Peng M; Yin W; Liu D; Ren H
Virol J; 2023 Feb; 20(1):22. PubMed ID: 36750902
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.
Zhou Y; Chen Z; He Y; Peng X; Chang Y; Tan A; Li H; Cai D; Hu P; Chen M; Peng M; Xu H; Ren H
Front Cell Infect Microbiol; 2023; 13():1201101. PubMed ID: 37457966
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
12. Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection.
He T; Zhou Y; Xu P; Ling N; Chen M; Huang T; Zhang B; Yang Z; Ao L; Li H; Chen Z; Zhang D; Shi X; Lei Y; Wang Z; Zeng W; Hu P; Lan Y; Zhou Z; Kang J; Huang Y; Shi T; Pan Q; Zhu Q; Ran X; Zhang Y; Song R; Xiang D; Xiao S; Zhang G; Shen W; Peng M; Cai D; Ren H
Liver Int; 2022 Jun; 42(6):1287-1296. PubMed ID: 35107848
[TBL] [Abstract][Full Text] [Related]
13. Association between immunosuppressants and poor antibody responses to SARS-CoV-2 vaccines in patients with autoimmune liver diseases.
Li H; Wang Y; Ao L; Ke M; Chen Z; Chen M; Peng M; Ling N; Hu P; Cai D; Zhang D; Ren H
Front Immunol; 2022; 13():988004. PubMed ID: 36275639
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
[TBL] [Abstract][Full Text] [Related]
16. Detection of specific RBD
Del Pino Molina L; Bravo Gallego LY; Nozal P; Soto-Serrano Y; Martínez-Feito A; Reche-Yebra K; González-Torbay A; Cuesta-Martín de la Cámara R; Gianelli C; Cámara C; González-García J; González-Muñoz M; Rodríguez-Pena R; López Granados E
Front Immunol; 2023; 14():1136308. PubMed ID: 37215146
[TBL] [Abstract][Full Text] [Related]
17. The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia.
Yang L; Liu Y; Guo Q; Jiang D
Open Med (Wars); 2023; 18(1):20230780. PubMed ID: 37693840
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.
Gao R; Zheng C; Yang M; Dai L; Chen C; Yao J; Zhang Z; Tang L; Shi Y; Han X
Expert Rev Vaccines; 2023; 22(1):1102-1113. PubMed ID: 37878494
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
[No Abstract] [Full Text] [Related]
20. Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
Huang J; Qiu Y; Luo L; Wu J; Hu D; Zhong X; Lin J; Guo L; Yang H; Li C; Wang X
J Med Virol; 2024 Mar; 96(3):e29542. PubMed ID: 38506170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
